SEINE BIO · SCIENCE LIBRARY
FOXO4-DRI
FOXO4-DRI is an experimental peptide designed to interfere with a protein interaction involved in senescent-cell survival.
Research compoundA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of FOXO4-DRI.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Overview
FOXO4-DRI is an experimental D-retro-inverso peptide designed to interfere with a molecular interaction associated with senescent cells. It is not simply the naturally occurring FOXO4 protein. Its role in laboratory senolytic research should not be translated into a commercial claim that it rejuvenates people or safely removes all harmful aging cells.
Community Use
PeptideDosages.com publishes community protocol material for FOXO4-DRI. Longevity discussions often focus on senescent-cell clearance. That research concept does not establish an appropriate patient population, a safe cycle, or a proven anti-aging outcome; informal schedules cannot resolve those clinical questions.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Weeks 1–4: 250 mcg; weeks 5–8: 375 mcg; weeks 9–16: 500 mcg | Once daily | 8–16 weeks Break: 8–12 weeks in the time-off section | Published informal biohacking claim PepGuru |
| Subcutaneous | 5 mg | Once daily | 3–5 days Break: 8–12 weeks | Published informal biohacking claim Peptide Protocol Portal |
Important context: FOXO4-DRI denotes a specific D-retro-inverso interfering peptide, not the FOXO4 protein or an arbitrary FOXO4 fragment. Primary cited work used cell cultures and mice. No common numerical regimen or safe maximum follows; mouse study amounts were not converted to humans.
Additional sources: Baar et al., Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging, Cell (2017). Consult the linked record for its exact formulation, population and methods.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
No FDA-approved FOXO4-DRI regimen exists. A mouse exposure cannot be scaled into a personal amount, and an intermittent community cycle is not a validated label. The protocol chart preserves source claims rather than instructions. Any human research program would need its own characterized product, protocol, and monitoring.
Research Findings
The 2017 Cell paper examined senescent cells and mouse models, including treatment-related and age-associated dysfunction. Disrupting the FOXO4–p53 interaction promoted apoptosis in the experimental setting. The paper did not establish clinical rejuvenation, functional improvement, or safety in treated human participants.
U.S. Approval & Access
FOXO4-DRI is not FDA-approved. A published animal experiment and a retail research listing are not an authorized patient-treatment pathway. Legal clinical research requires actual oversight and eligibility criteria. An educational consultation can explain the work but does not guarantee access to the peptide.
What It Does in the Body
The proposed action targets a survival-related interaction in certain senescent cells. Selective activity in an experimental model does not establish that every senescent cell is harmful or that whole-body removal will be beneficial. A cell-killing mechanism needs especially careful translation from model systems to clinical outcomes and safety. For the uses discussed here, reliable clinical onset, peak benefit, and duration are not established. Route-specific human peak exposure and persistence cannot be inferred from community schedules or a laboratory response.
Benefits & Reported Experiences
Changes in mouse function cannot establish restored mobility, youthfulness, or longer human life. A meaningful human result would require direct testing in a defined population with functional outcomes and adequate follow-up. Neither a mechanistic diagram nor a community report can supply a dependable transformation timeline.
Side Effects & Risks
The source set does not establish human adverse-event rates, long-term tissue effects, or interactions for informal use. Removing cells is not inherently safer than stimulating them. A clinician should distinguish a selective experimental finding from a guarantee that the same intervention spares every important tissue in a person.
Delivery Options
Experimental delivery conditions do not validate a consumer product or route. This page provides no injection, preparation, dose-conversion, or senolytic-cycle instructions. A supplier’s vial size cannot recreate the biological context, product controls, or oversight of the published experiments.
Product Quality & Storage
The precise D-retro-inverso construct matters when matching a product to the paper. A material described only as FOXO4 may not be the studied peptide. Quality testing can identify a compound but cannot establish safe senolysis, clinical benefit, or authorization to use that material in patients. Storage must follow the authorized finished product’s labeling or an approved study protocol; temperatures and beyond-use times cannot be inferred from research-vial guidance.
Combinations & Interactions
Pairing FOXO4-DRI with other senolytics or longevity peptides creates an additional experimental exposure. Separate studies do not demonstrate that the effects combine safely or improve outcomes. The cited paper does not validate a consumer stack, and no timing or combination schedule is supplied.
Talking With Your Provider
For aging-related symptoms or functional limitations, seek assessment of the actual condition and discuss established care. If legitimate research participation is relevant, ask about the specific trial, oversight, endpoints, and consent. Educational interest in senolysis does not imply a treatment offer or a rejuvenation guarantee.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Cellular, mitochondrial & longevity researchEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →